The Role of Antibody in Herpes Simplex Virus Infection in Humans

Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 179)


This chapter will attempt to critically analyze the role of antibody in the host’s response to herpes simplex virus (HSV) infection. Although the emphasis will be on the human, where relevant, selected animal data will be included.


Herpes Simplex Virus Infection Acyclovir Therapy Genital Herpes Simplex Virus Infection Neonatal Herpes Simplex Virus Infection Primary Herpes Simplex Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ashe WK, Notkins AL (1967) Kinetics of sensitization of herpes simplex virus and its relationship to the reduction in the neutralization rate constant. Virology 33: 613–617PubMedCrossRefGoogle Scholar
  2. Ashley RL, Corey L (1984) Effect of acyclovir treatment of primary genital herpes on the antibody response to herpes simplex virus. J Clin Invest 73: 681–688PubMedCrossRefGoogle Scholar
  3. Ashley R, Mack R, Critchlow C, Shurtleff M, Corey L (1988) Differential effect of systemic acyclovir treatment of genital HSV-2 infections on antibody responses to individual HSV-2 proteins. J Med Virol 24: 309–320PubMedCrossRefGoogle Scholar
  4. Balachandran N, Bacchetti S, Rawls WE (1982) Protection against lethal challenge of BalB/C mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2. Infect Immun 37:1132–1137PubMedGoogle Scholar
  5. Baron S, Worthingon MG, Williams J, Gaines JW (1976) Post exposure serum prophylaxis of neonatal herpes simplex virus infection of mice. Nature 261: 505–506PubMedCrossRefGoogle Scholar
  6. Bernstein Dl, Lovett MA, Bryson YJ (1984) The effects of acyclovir on antibody response to herpes simplex virus in primary genital herpetic infections. J Infect Dis 150: 7–13PubMedCrossRefGoogle Scholar
  7. Biron CA, Bryon KS, Sullivan JL (1989) Severe herpes virus infections in an adolescent without natural killer cells. N Eng J Med 320:1731–1735CrossRefGoogle Scholar
  8. Blacklaws BA, Krishna S, Minson AC, Nash AA (1990) Immunogenicity of herpes simplex virus type 2 glycoproteins expressed in vaccinia virus recombinants. Virology 177: 727–736PubMedCrossRefGoogle Scholar
  9. Blacklaws BA, Nash AA, Darby G (1987) Specificity of the immune response of mice to herpes simplex virus glycoprotein B and D constituitively expressed on L cell lines. J Gen Virol 68:1103–1114PubMedCrossRefGoogle Scholar
  10. Brown ZA, Benedetti J, Ashley R, Burchett S, Selke S, Berry S, Vontver LA, Corey L (1991) Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor Engl J Med 324: 1247–1252CrossRefGoogle Scholar
  11. Brunell PA, Ross A, Miller LH, Kuo B (1969) Prevention of varicella by zoster immunoglobulin. N Engl J Med 280:1191–1194PubMedCrossRefGoogle Scholar
  12. Conley ME, Park CL, Douglas SD (1986) Childhood common variable immunodeficiency with auto-immune disease, J Pediatr 108: 915–922PubMedCrossRefGoogle Scholar
  13. Corey L, Adams HG, Brown ZA, Holmes KK (1983) Genital herpes simplex virus infections, clinical manifestations, course, and complications. Ann Intern Med 98: 958–972PubMedGoogle Scholar
  14. Davis WB, Taylor JA, Oakes JE (1979) Ocular infection with herpes simplex virus type 1: prevention of acute herpetic encephalitis by systemic administration of virus specific antibody. J Infect Dis 140: 534–540PubMedCrossRefGoogle Scholar
  15. Dix RD, Pereira L, Baringer JR (1981) Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease. Infect Immun 34: 192–199PubMedGoogle Scholar
  16. Erlich KS, Hauer L, Mills J (1988) Effects of long-term acyclovir chemosuppression on serum IgG anti-body to herpes simplex virus. J Med Virol 26: 33–39PubMedCrossRefGoogle Scholar
  17. Frenkel L, Pineda E, Garratty E, Fall H, Dilon M, Bryson Y (1989) A perspective study of the effects of acyclovir treatment on the HSV-2 lymphoproliferative response of persons with frequently recurring HSV-2 genital infection. J Infect Dis 159: 845–850PubMedCrossRefGoogle Scholar
  18. Geiser CF, Bishop Y, Myers M, Jaffe N, Yankee R (1975) Prophylaxis of varicella in children with neoplastic disease: comparative results with zoster immune plasma and gamma globulin. Cancer 35: 1027–1030PubMedCrossRefGoogle Scholar
  19. Georgiades JA, Montgomery J, Hughes TK, Jensen D, Baron S (1982) Determinants of protection by human immune globulin against experimental herpes neonatorum. Proc Soc Exp Biol Med 170:291–297PubMedGoogle Scholar
  20. Gershon AA, Steinberg S, Brunell PA (1974) Zoster immune globulin. A further assessment. N Engl J Med 290: 243–245PubMedCrossRefGoogle Scholar
  21. Gold D, Ashley R, Solberg G, Abbo H, Corey L (1988) Chronic-dose acyclovir to suppress frequently recurring genital herpes simplex virus infection: effect on antibody response to herpes simplex virus type 2 proteins. J Infect Dis 158: 1227–1234PubMedCrossRefGoogle Scholar
  22. Greenberg MS, Friedman H, Cohen SG, Oh SH, Laster L, Starr S (1987) A comparative study of herpes simplex infections in renal transplant and leukemic patients. J Infect Dis 156: 280–287PubMedCrossRefGoogle Scholar
  23. Hayashi Y, Wada T, Mori R (1983) Protection of newborn mice against herpes simplex virus infection by prenatal and postnatal transmission of antibody. J Gen Virol 64:1007–1012PubMedCrossRefGoogle Scholar
  24. Hayashida I, Nagafuchi S, Hayashi Y, Kino Y, Mori R, Oda H, Ohtomo N, Tashiro A (1982) Mechanism of antibody-mediated protection against herpes simplex virus infection in athymic nude mice: Requirement of Fc portion of antibody. Microbiol Immunol 26: 497–509PubMedGoogle Scholar
  25. Kahlon J, Whitley RJ (1988) Antibody response of the newborn after herpes simplex virus infection. J Infect Dis 158: 925–933PubMedCrossRefGoogle Scholar
  26. Kilbourne EM, Horsfall FL Jr (1951) Studies of herpes simplex virus in newborn mice. J Immunol 67: 321–329PubMedGoogle Scholar
  27. Kino Y, Eto T, Ohtomo N, Hayashi Y, Yamamoto M, Mori R (1985) Passive immunization of mice with monoclonal antibodies to glycoprotein gB of herpes simplex virus. Microbiol Immunol 29:143–149PubMedGoogle Scholar
  28. Kohl S (1987) Postnatal herpes simplex virus infections. In: Feigin RD, Cherry JD (eds) Textbook of pediatric infectious diseases, 2nd. Saunders, Philadelphia, pp 1577–1601Google Scholar
  29. Kohl S (1990) A hypothesis on the pathophysiology of neonatal herpes simplex virus encephalitis: clinical recurrence after asymptomatic primary infection. Pediatr Infect Dis J 9: 307–308PubMedCrossRefGoogle Scholar
  30. Kohl S (1991) Role of antibody-dependent cellular cytotoxicity in defense against herpes simplex virus infection. Rev Infect Dis 13:108–114PubMedCrossRefGoogle Scholar
  31. Kohl S, Erisson CD (1982) Cellular cytotoxocity to herpes simplex virus-infected cells of leukocytes from patients with serious burns. Clin Immunol Immunopathol 24:171–178PubMedCrossRefGoogle Scholar
  32. Kohl S, Loo LS (1982) Protection of neonatal mice against herpes simplex virus infection. Probable in vivo antibody-dependent cellular cytoxocity. J Immunol 129: 370–376PubMedGoogle Scholar
  33. Kohl S, Loo LS (1984) The relative role of transplacental and milk immune transfer in protection against lethal neonatal herpes simplex virus infection in mice. J Infect Dis 149: 38–42PubMedCrossRefGoogle Scholar
  34. Kohl S, Shaban SS, Starr SE, Wood PA, Nahmias AJ (1978) Human neonatal and maternal monocyte-macrophage and lymphocyte-mediated antibody-dependent cytotoxicity to cells infected with herpes simplex. J Pediatr 93: 206–210PubMedCrossRefGoogle Scholar
  35. Kohl S, Loo LS, Pickering LK (1981) Protection of neonatal mice against herpes simplex viral infection by human antibody and leukocytes from adult but not neonatal humans. J Immunol 127:1273–1275PubMedGoogle Scholar
  36. Kohl S, Loo LS, Gonick B (1984) Analysis in human neonates of defective antibody-dependent cellular cytotoxicity and natural killer cytotoxicity to herpes simplex virus-infected cells. J Infect Dis 150: 14–19PubMedCrossRefGoogle Scholar
  37. Kohl S, Loo LS, Schmalstieg FS, Anderson DC (1986) The genetic deficiency of leukocyte surface glycoprotein Mac-1, LFA-1, p150, 95 in humans in associated with defective antibody-dependent cellular cytotoxicity in vitro and defective protection against herpes simplex virus infection in vivo. J Immunol 137:1688–1694PubMedGoogle Scholar
  38. Kohl S, Loo LS, Rench MA, Noya FSD, Feldman S, Baker CJ (1989a) Effect of intravenously administered immune globulin on functional antibody to herpes simplex virus in low birth weight neonates. J Pediatr 115:135–139PubMedCrossRefGoogle Scholar
  39. Kohl S, West MS, Prober CG, Loo LS, Sullander W, Arvin AM (1989b) Neonatal antibody-dependent cellular cytotoxicity antibody levels are associated with the clinical presentation of neonatal herpes simplex virus infection. J Infect Dis 160: 770–776PubMedCrossRefGoogle Scholar
  40. Kohl S, Strynadka NCJ, Hodges RS, Pereira L (1990) Analysis of the role of antibody-dependent cellular cytotoxicity antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B. J Clin Invest 86: 273–278PubMedCrossRefGoogle Scholar
  41. Lafferty WE, Brewer LA, Corey L (1984) Alteration of lymphocyte transformation response to herpes simplex virus by acyclovir therapy. Antimicrob Agents Chemother 26: 887–891PubMedGoogle Scholar
  42. Levin MJ, Leary PL, Arbeit RD (1980) Effect of acyclovir on the proliferation of human fibroblasts and peripheral blood mononuclear cells. Antimicrob Agents Chemother 17: 947–953PubMedGoogle Scholar
  43. Linneman CC Jr, May DB, Schubert WK, Caraway CT, Schiff GM (1973) Fatal viral encephalitis in children with X-linked hypogammaglobulinemia. Am J Dis Child 126: 100–103Google Scholar
  44. Ljungman P, Wilizek H, Gahrton G, Gustavsson A, Lundgren G, Lonnqvist B, Ringden O, Wahren B (1986) Long-term acyclovir prophylaxis is bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant 1:185–192PubMedGoogle Scholar
  45. Lopez C, O’Reilly RJ (1977) Cell-mediated immune responses in recurrent herpes virus infections. J Immunol 118: 895–902PubMedGoogle Scholar
  46. Luyet F, Samra D, Soneji A, Marks Ml (1975) Passive immunization in experimental herpes virus hominis infection of newborn mice. Infect Immun 12:1258–1261PubMedGoogle Scholar
  47. McKendall RR (1985) IgG-mediated viral clearance in experimental infection with herpes simplex virus type 1: role for neutralization and Fc-dependent functions but not CI cytolysis and C5 chemotaxis. J Infect Dis 151: 464–470PubMedCrossRefGoogle Scholar
  48. McKendall RR, Klassen T, Baringer JR (1979) Host defenses in herpes simplex infections of the nervous system: Effect of antibody on disease and viral spread. Infect Immun 23: 305–311PubMedGoogle Scholar
  49. Mester JC, Glorioso JC, Rouse BT (1991) Protection against zosteriform spread of herpes simplex virus by monoclonal antibodies. J Infect Dis 163: 263–269PubMedCrossRefGoogle Scholar
  50. Nahmias AJ, Josey WE, Naib ZM, Freeman MG, Fernandez RJ, Wheeler JH (1971) Perinatal risk associated with maternal genital herpes simplex virus infection. Am J Obstet Gynecol 110: 825–837PubMedGoogle Scholar
  51. Oakes JE, Lausch RN (1981) Role of Fc fragment in antibody-mediated recovery from ocular and subcutaneous herpes simplex virus infections. Infect Immun 33:109–114PubMedGoogle Scholar
  52. Oakes JE, Rosemond-Hornbeak H (1978) Antibody-mediated recovery from subcutaneous herpes simplex virus type 2 infection. Infect Immun 21: 489–495PubMedGoogle Scholar
  53. Oakes JE, Davis WB, Taylor JA, Weppner WA (1980) Lymphocyte reactivity contributes to protection conferred by specific antibody passively transferred to herpes simplex virus-infected mice. Infect Immun 29: 642–649PubMedGoogle Scholar
  54. Ogra SS, Weintraub D, Ogra PL (1977) Immunologic aspects of human colostrum and milk. III. Fate and adsorption of cellular and soluble components in the gastrointestinal tract of the newborn. J Immunol 119: 245–248PubMedGoogle Scholar
  55. Oh SH, Douglas JM, Corey L, Kohl S (1989) Kinetics of the humoral immune response measured by antibody-dependent cell-mediated cytotoxicity and neutralization assays in genital herpes simplex infections. J Infect Dis 159: 328–330PubMedCrossRefGoogle Scholar
  56. Olson NY, Hall JC (1987) Chronic cutaneous herpes simplex and X-linked hypogammaglobulinemia. Pediatr Dermatol 4: 225–228PubMedCrossRefGoogle Scholar
  57. Openshaw H, Asher LVS, Wohlenberg C, Sekizawa T, Notkins AL (1979) Acute and latent infection of sensory ganglia with herpes simplex virus: immune control and virus reactivation. J Gen Virol 44:205–215PubMedCrossRefGoogle Scholar
  58. Orenstein WA, Heymann DL, Ellis RJ, Rosenberg RL, Nakano J, Halsey NA, Overturf GD, Hayden GF, Witte JS (1981) Prophylaxis of varicella in high risk children: dose-response effect of zoster immune globulin. J Pediatr 98: 368–373PubMedCrossRefGoogle Scholar
  59. Pass RF, Whitley RS, Whelchel JD, Diethelm AG, Reynolds DW, Alford CA (1979) Identification of patients with increased risk of infection with herpes simplex virus after renal transplantation. J Infect Dis 140: 487–492PubMedCrossRefGoogle Scholar
  60. Prober CG, Sullender WM, Yasukawa LL, Au DS, Yeager AS, Arvin AM (1987) Low risk of herpes simplex virus infection in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infection. N Engl J Med 316: 240–244PubMedCrossRefGoogle Scholar
  61. Rager-Zisman B, Allison AC (1976) Mechanism of immunologic resistance to herpes simplex virus 1 (HSV-1) infection. J Immunol 116: 35–40PubMedGoogle Scholar
  62. Rector JT, Lausch RN, Oakes JE (1982) Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection. Infect Immun 38:168–174PubMedGoogle Scholar
  63. Rector JT, Lausch RN, Oakes JE (1984) Identification of infected cell-specific monoclonal antibodies, and their role in host resistance to ocular herpes simplex virus type 1 infection. J Gen Virol 65: 657–666PubMedCrossRefGoogle Scholar
  64. Sekizawa T, Openshaw H, Wohlenberg C, Notkins AL (1980) Latency of herpes simplex virus in absence of neutralizing antibody: Model for reactivation. Science 210:1026–1028PubMedCrossRefGoogle Scholar
  65. Shore SL, Black CM, Melewicz FM, Wood PA, Nahmias AJ (1976) Antibody-dependent cell mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus. J Immunol 116: 194–201PubMedGoogle Scholar
  66. Shore SL, Melewicz FM, Gordon DS (1977a) The mononuclear cell in human blood which mediates antibody dependent cellular cytotoxicity to virus-infected target cells: I. Identification of the population of effector cells. J Immunol 118: 558–566PubMedGoogle Scholar
  67. Shore SL, Milgrom H, Wood P, Nahmias AJ (1977b) Neonatal function of antibody-dependent cell-mediated cytotoxicity to target cells infected with herpes simplex virus. Pediatrics 59: 22–28PubMedGoogle Scholar
  68. Simmons A, Nash AA (1985) Role of antibody in primary and recurrent herpes simplex virus infection. J Virol 53: 944–948PubMedGoogle Scholar
  69. Smith RN, Hanna L (1974) Herpes virus infections in pregnancy: a comparison of neutralizing antibody titers in mothers and their infants. Am J Obstet Gynecol 119: 314–318PubMedGoogle Scholar
  70. Snydman DR (1990) Cytomegalovirus immunoglobulins in the prevention and treatment of cyto-megalovirus disease. Rev Infect Dis 12: S839-S848PubMedCrossRefGoogle Scholar
  71. Steele RW, Marmer DJ, Keeney RE (1980) Comparative in vitro immunotoxicology of acyclovir and other antiviral agents. Infect Immun 28: 957–962PubMedGoogle Scholar
  72. Stevens JG, Cook ML (1974) Maintenance of latent herpetic infection: an apparent role for anti-viral IgG. J Immunol 113:1685–1693PubMedGoogle Scholar
  73. Strulovitch C, Marks Ml, Soneji A, Goldberg S (1979) Immunotherapy and drugs in neonatal disseminated herpes simplex virus type 2: a mouse model. J Antimicrob Chemother 5: 437–446PubMedCrossRefGoogle Scholar
  74. Sullender WM, Miller JL, Yasukawa LL, Bradley JS, Black SB, Yeager AS, Arvin AM (1987) Humoral and cell-mediated immunity in neonates with herpes simplex virus infection. J Infect Dis 155: 28–37PubMedCrossRefGoogle Scholar
  75. Sullender WM, Yasukawa LL, Schwartz M, Pereira L, Hensleigh PA, Prober CG, Arvin AM (1988) Type-specific antibodies to herpes simplex virus type 2 (HSV-2) glycoprotein G in pregnant women, infants exposed to maternal HSV-2 infection at delivery, and infants with neonatal herpes. J Infect Dis 157:164–171PubMedCrossRefGoogle Scholar
  76. Thong YH, Vincent MM, Hensen SA, Fuccillo DA, Rola-Pleszczynski M, Bellanti JA (1975) Depressed specific cell-mediated immunity to herpes simplex virus type 1 in patients with recurrent herpes labialis. Infect Immun 12: 76–80PubMedGoogle Scholar
  77. Wade JC, Day LM, Crowley JJ, Meyers JD (1984a) Recurrent infection with herpes simplex virus after marrow transplantation: role of the specific immune response and acyclovir treatment. J Infect Dis 149: 750–756PubMedCrossRefGoogle Scholar
  78. Wade JC, Newton B, Flournoy N, Meyers JD (1984b) Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 100: 823–828PubMedGoogle Scholar
  79. Whitley RJ, Nahmias AJ, Visintine AM, Fleming CL, Alford CA (1980) The natural history of herpes simplex virus infection of mother and newborn. Pediatrics 66: 489–494PubMedGoogle Scholar
  80. Whitley RJ, Yeager A, Kartus B, Bryson Y, Connor JD, Alford CA, Nahmias A, Soong S-J (1983) Neonatal herpes simplex virus infection: follow-up evaluation of Vidarabine therapy. Pediatrics 72: 778–785PubMedGoogle Scholar
  81. Whitley RJ, Corey L, Arvin A, Lakeman FD, Sumaya CV, Wright PF, Dunkle LM, Steele RW, Soong SJ, Nahmias AJ, Alford CA, Powell DA, San Joquin V (NIAID Collaborative Antiviral Study Group) (1988). Changing presentation of herpes simplex virus infection in neonates. J Infect Dis 158:109–116PubMedCrossRefGoogle Scholar
  82. Willey DE, Cantin EM, Hill LR, Moss B, Notkins AL, Openshaw H (1988) Herpes simplex virus type 1-vaccinia recombinant expressing glycoprotein B: protection from acute and latent infection. J Infect Dis 158: 1382–1386PubMedCrossRefGoogle Scholar
  83. Wilton JMA, Ivanyi L, Lehner T (1972) Cell-mediated immunity in herpes virus hominis infections. Br Med J 1: 723–726PubMedCrossRefGoogle Scholar
  84. Winston DJ, How G, Lin CH, Bartoni K, Budinger MD, Gale RP, Champlin RE (1987) Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial penumonia after bone marrow transplantation. Ann Intern Med 106: 12–18PubMedGoogle Scholar
  85. Yeager AS, Arvin AM, Urbani LJ, Kemp JA (1980) Relationship of antibody to outcome in neonatal herpes simplex virus infections. Infect Immun 29: 532–538PubMedGoogle Scholar
  86. Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JE, Prober CG (1981) Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 98: 281–287PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin, Heidelberg 1992

Authors and Affiliations

  • S. Kohl
    • 1
    • 2
  1. 1.Division of Infectious Diseases, Department of PediatricsUniversity of California Medical SchoolSan FranciscoUSA
  2. 2.San Francisco General HospitalSan FranciscoUSA

Personalised recommendations